Literature DB >> 16847408

Effectiveness of highly-active antiretroviral therapy by race/ethnicity.

Michael J Silverberg1, Scott A Wegner, Mark J Milazzo, Rosemary G McKaig, Carolyn F Williams, Brian K Agan, Adam W Armstrong, Stephen J Gange, Clifton Hawkes, Robert J O'Connell, Sunil K Ahuja, Matthew J Dolan.   

Abstract

OBJECTIVE: To determine the effectiveness of HAART by race/ethnicity.
DESIGN: Prospective multicenter cohort study.
METHODS: We studied 991 African-Americans and 911 European-Americans enrolled in the United States Military's Tri-Service AIDS Clinical Consortium Natural History Study who had dates of HIV seroconversion known within 5 years and followed between 1990 and 2002. We determined the rate of disease progression to AIDS and death for subjects in this cohort. Multivariable models evaluated race, pre-HAART (1990-1995) and HAART (1996-2002) eras, age, gender and military service.
RESULTS: In the pre-HAART era, African-Americans had a statistically nonsignificant trend towards better outcomes: the relative hazards (RH) of AIDS and death for African-Americans compared to European-Americans were 0.85 [95% confidence interval (CI), 0.68-1.05] and 0.77 (95% CI, 0.55-1.08), respectively. In the HAART era, outcomes were similar by race: 1.17 (95% CI, 0.86-1.61) for AIDS and 1.11 (95% CI, 0.81-1.53) for death with overlapping Kaplan-Meier curves. Relative to the pre-HAART era, the adjusted RH of AIDS in the HAART era was 0.41 (95% CI, 0.31-0.54) and 0.30 (95% CI, 0.22-0.40) for African-American and European-American participants, respectively. Analogous RH for death were 0.55 (95% CI, 0.38-0.80) and 0.38 (95% CI, 0.27-0.54). The precipitous declines in AIDS and death in the HAART era were not statistically different by race.
CONCLUSIONS: : In a large multi-racial cohort with equal access to health care, HIV treatment outcomes by race/ethnicity were similar.

Entities:  

Mesh:

Year:  2006        PMID: 16847408     DOI: 10.1097/01.aids.0000237369.41617.0f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

1.  Age at cancer diagnosis among persons with AIDS in the United States.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Eric A Engels
Journal:  Ann Intern Med       Date:  2010-10-05       Impact factor: 25.391

2.  Bayesian posterior distributions without Markov chains.

Authors:  Stephen R Cole; Haitao Chu; Sander Greenland; Ghassan Hamra; David B Richardson
Journal:  Am J Epidemiol       Date:  2012-02-03       Impact factor: 4.897

3.  Efficient quantification of HIV-1 in heparin plasma spiked with cultured HIV-1 by the Roche Cobas TaqMan and Abbott RealTime HIV-1 tests.

Authors:  Linda L Jagodzinski; Holly R Weston; Ying Liu; Robert J O'Connell; Sheila A Peel
Journal:  J Clin Microbiol       Date:  2012-06-06       Impact factor: 5.948

4.  Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

Authors:  Thomas P Giordano; Glenn Bartsch; Yafeng Zhang; Ellen Tedaldi; Judith Absalon; Sharon Mannheimer; Avis Thomas; Rodger D MacArthur
Journal:  AIDS Patient Care STDS       Date:  2010-05       Impact factor: 5.078

5.  Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy.

Authors:  Michael J Silverberg; Lisa P Jacobson; Audrey L French; Mallory D Witt; Stephen J Gange
Journal:  J Pain Symptom Manage       Date:  2009-03-28       Impact factor: 3.612

6.  Hospitalization rates of people living with HIV in the United States, 2009.

Authors:  Marcus A Bachhuber; William N Southern
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

7.  Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Authors:  Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2013-09-17       Impact factor: 9.079

8.  Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care.

Authors:  Michael J Silverberg; Wendy Leyden; Charles P Quesenberry; Michael A Horberg
Journal:  J Gen Intern Med       Date:  2009-07-16       Impact factor: 5.128

9.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.

Authors:  Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan
Journal:  AIDS Res Ther       Date:  2010-05-27       Impact factor: 2.250

10.  The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry.

Authors:  Hemant Kulkarni; Vincent C Marconi; Weijing He; Michael L Landrum; Jason F Okulicz; Judith Delmar; Dickran Kazandjian; John Castiblanco; Seema S Ahuja; Edwina J Wright; Robin A Weiss; Robert A Clark; Matthew J Dolan; Sunil K Ahuja
Journal:  Blood       Date:  2009-07-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.